PCMC
VIRX

Planning Capital Management Corporation’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Planning Capital Management Corporation’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.68K Hold
7,272
– – ﹤0.01% 606
2024
Q2 		$3.95K Hold
7,272
– – ﹤0.01% 480
2024
Q1 		$7.42K Hold
7,272
– – 0.01% 447
2023
Q4 		$4.15K Buy
+7,272
New +$4.46K ﹤0.01% 504

Other funds holding VIRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Planning Capital Management Corporation's VIRX Position: Q3 2024 in Review

Planning Capital Management Corporation held its Viracta Therapeutics, Inc. Common Stock (VIRX) position steady in Q3 2024 at 7,272 shares worth $1.68K. The position accounts for ﹤0.01% of the portfolio, ranked #606.

Planning Capital Management Corporation first reported a position in VIRX in Q4 2023 and has held it in 4 quarters since. The position peaked at $7.42K in Q1 2024. 38 funds tracked by Wall St. Rank hold VIRX as of Q3 2024.

  • Planning Capital Management Corporation held 7,272 shares of Viracta Therapeutics, Inc. Common Stock worth $1.68K as of Q3 2024.
  • Planning Capital Management Corporation left its Viracta Therapeutics, Inc. Common Stock share count unchanged in Q3 2024.
  • Viracta Therapeutics, Inc. Common Stock made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #606 holding.
  • Planning Capital Management Corporation first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2023 and has held it in 4 quarters since.
  • Planning Capital Management Corporation's Viracta Therapeutics, Inc. Common Stock position peaked at $7.42K in Q1 2024.
  • 38 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.